KYMR · Categories · Offerings
KYMR - Public offerings
Kymera Therapeutics Inc. (KYMR) public offerings - real-time wire coverage filtered to Offerings only.
Recent Offerings for KYMR
- Kymera Therapeutics Announces Closing of Upsized $602 Million Public Offering and Full Exercise of Underwriters' Option to Purchase Additional SharesWATERTOWN, Mass., Dec. 11, 2025 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ:KYMR), a clinical-stage biopharmaceutical company advancing a new class of oral small molecule degrader medicines for immunological diseases, today announced the closing of its upsized underwritten public offering of $602.0 million of shares of its common stock. Kymera sold and issued 8,050,000 shares of its common stock, which includes 1,050,000 shares sold and issued upon the full exercise by the underwriters of their option to purchase additional shares of common stock. The shares of common stock were sold at a public offering price of $86.00 per share. The gross proceeds to Kymera from the offering we
- Kymera Therapeutics Announces Pricing of Upsized $602 Million Public OfferingWATERTOWN, Mass., Dec. 09, 2025 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ:KYMR), a clinical-stage biopharmaceutical company advancing a new class of oral small molecule degrader medicines for immunological diseases, today announced the pricing of its underwritten public offering of $602.0 million of shares of its common stock. Kymera is selling 7,000,000 shares of common stock in the offering, which are being sold at a public offering price of $86.00 per share. In addition, Kymera has granted the underwriters a 30-day option to purchase up to an additional 1,050,000 shares of its common stock at the public offering price per share, less underwriting discounts and commissions. T
- Kymera Therapeutics Announces Proposed Public OfferingWATERTOWN, Mass., Dec. 08, 2025 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ:KYMR), a clinical-stage biopharmaceutical company advancing a new class of oral small molecule degrader medicines for immunological diseases, today announced that it has commenced an underwritten public offering of $500.0 million of shares of its common stock. All of the shares of common stock to be sold in this offering are being offered by Kymera. In addition, Kymera intends to grant the underwriters a 30-day option to purchase up to an additional $75.0 million of shares of its common stock at the public offering price per share, less underwriting discounts and commissions. The proposed offering is subj
- Kymera Therapeutics Announces Pricing of $250 Million Public OfferingWATERTOWN, Mass., June 26, 2025 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ:KYMR), a clinical-stage biopharmaceutical company advancing a new class of oral small molecule degrader medicines for immunological diseases, today announced the pricing of its underwritten public offering of $250.8 million of shares of its common stock and, in lieu of common stock to certain investors, pre-funded warrants to purchase shares of its common stock. Kymera is selling 5,044,500 shares of common stock and, in lieu of common stock to certain investors, pre-funded warrants to purchase 655,500 shares of common stock in the offering. The shares of common stock are being sold at a public offering pr
- Kymera Therapeutics Announces Proposed Public OfferingWATERTOWN, Mass., June 25, 2025 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ:KYMR), a clinical-stage biopharmaceutical company advancing a new class of oral small molecule degrader medicines for immunological diseases, today announced that it has commenced an underwritten public offering of $250.0 million of shares of its common stock and, in lieu of common stock to certain investors, pre-funded warrants to purchase shares of its common stock. All of the shares of common stock and pre-funded warrants to be sold in this offering are being offered by Kymera. In addition, Kymera intends to grant the underwriters a 30-day option to purchase up to an additional $37.5 million of shares
- Kymera Therapeutics Announces Closing of Upsized $225 Million Public Offering and Full Exercise of Underwriters' Option to Purchase Additional SharesWATERTOWN, Mass., Aug. 21, 2024 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ:KYMR), a clinical-stage biopharmaceutical company advancing a new class of small molecule medicines using targeted protein degradation (TPD), today announced the closing of its upsized underwritten public offering of $225 million of shares of its common stock and, in lieu of common stock to certain investors, pre-funded warrants to purchase shares of its common stock. Kymera sold and issued 2,830,533 shares of its common stock, which includes 828,220 shares sold and issued upon the full exercise by the underwriters of their option to purchase additional shares of common stock and, in lieu of common stock
- Kymera Therapeutics Announces Pricing of $225 Million Public OfferingWATERTOWN, Mass., Aug. 19, 2024 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ:KYMR), a clinical-stage biopharmaceutical company advancing a new class of small molecule medicines using targeted protein degradation (TPD), today announced the pricing of its underwritten public offering of $225 million of shares of its common stock and, in lieu of common stock to certain investors, pre-funded warrants to purchase shares of its common stock. Kymera is selling 2,002,313 shares of common stock and, in lieu of common stock to certain investors, pre-funded warrants to purchase 3,519,159 shares of common stock in the offering. The shares of common stock are being sold at a public offering pr
- Kymera Therapeutics Announces Proposed Public OfferingWATERTOWN, Mass., Aug. 19, 2024 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ:KYMR), a clinical-stage biopharmaceutical company advancing a new class of small molecule medicines using targeted protein degradation (TPD), today announced that it has commenced an underwritten public offering of $200.0 million of shares of its common stock and, in lieu of common stock to certain investors, pre-funded warrants to purchase shares of its common stock. All of the shares of common stock and pre-funded warrants to be sold in this offering are being offered by Kymera. In addition, Kymera intends to grant the underwriters a 30-day option to purchase up to an additional $30.0 million of shares
- Kymera Therapeutics Announces Closing of Upsized $275 Million Public Offering and Full Exercise of Underwriters' Option to Purchase Additional SharesWATERTOWN, Mass., Jan. 09, 2024 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ:KYMR), a clinical-stage biopharmaceutical company advancing a new class of small molecule medicines using targeted protein degradation (TPD), today announced the closing of its upsized underwritten public offering of $275 million of shares of its common stock and, in lieu of common stock to certain investors, pre-funded warrants to purchase shares of its common stock. Kymera sold and issued 3,884,158 shares of its common stock, which includes 1,633,663 shares sold and issued upon the exercise in full by the underwriters of their option to purchase additional shares of common stock and, in lieu of common s
- Kymera Therapeutics Announces Pricing of $275 Million Public OfferingWATERTOWN, Mass., Jan. 05, 2024 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ:KYMR), a clinical-stage biopharmaceutical company advancing a new class of small molecule medicines using targeted protein degradation (TPD), today announced the pricing of its underwritten public offering of $275 million of shares of its common stock and, in lieu of common stock to certain investors, pre-funded warrants to purchase shares of its common stock. Kymera is selling 2,250,495 shares of common stock and, in lieu of common stock to certain investors, pre-funded warrants to purchase 8,640,594 shares of common stock in the offering. The shares of common stock are being sold at a public offering pr
- Kymera Therapeutics Announces Proposed Public OfferingWATERTOWN, Mass., Jan. 04, 2024 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ:KYMR), a clinical-stage biopharmaceutical company advancing a new class of small molecule medicines using targeted protein degradation (TPD), today announced that it has commenced an underwritten public offering of $250.0 million of shares of its common stock and, in lieu of common stock to certain investors, pre-funded warrants to purchase shares of its common stock. All of the shares of common stock and pre-funded warrants to be sold in this offering are being offered by Kymera. In addition, Kymera intends to grant the underwriters a 30-day option to purchase up to an additional $37.5 million of shares
- Kymera Announces $150 Million Private Placement Equity FinancingWATERTOWN, Mass., Aug. 19, 2022 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ:KYMR), a clinical-stage biopharmaceutical company advancing targeted protein degradation to deliver novel small molecule protein degrader medicines, has entered into a securities purchase agreement with certain existing and new accredited investors to issue and sell an aggregate of 2,769,228 shares of its common stock ("Common Stock") at a price of $26.00 per share and pre-funded warrants ("Pre-Funded Warrants") to purchase up to an aggregate of 3,000,000 shares of Common Stock at a purchase price of $25.9999 per pre-funded warrant share, through a private investment in public equity ("PIPE") financing. T
- Kymera Therapeutics to Report First Quarter 2022 Results and Announces Participation at Upcoming Investor ConferencesWATERTOWN, Mass., April 19, 2022 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ:KYMR), a clinical-stage biopharmaceutical company advancing targeted protein degradation to deliver novel small molecule protein degrader medicines, today announced that the Company will report first quarter 2022 financial results on May 3rd, 2022 and will host a conference call at 8AM ET. The Company will also participate in several upcoming investor conferences and events. "As Kymera approaches the two-year anniversary of our initial public offering and is now a clinical stage company across three unique programs, we will be providing a broad update on our programs and pipelines on our first quarterly
- Kymera Therapeutics Announces Second Quarter 2021 Financial Results and Provides a Business UpdatePositive interim results from Single Ascending Dose portion of Phase 1 trial of first-in-class oral IRAK4 degrader KT-474 demonstrated degrader proof-of-mechanism Recently initiated dosing of healthy volunteers in the Multiple Ascending Dose portion of Phase 1 trial of KT-474 Expect Investigational New Drug Applications for oncology degrader programs KT-413 and KT-333 in 2H 2021 Strong financial position after successful follow-on offering with pro forma cash position of $647 million to support continued company, pipeline, and platform expansion WATERTOWN, Mass., Aug. 06, 2021 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ:KYMR), a clinical-stage biopharmaceutical company advan
- Kymera Therapeutics Announces Closing of Upsized Public Offering of Common Stock and Full Exercise of Underwriters' Option to Purchase Additional SharesWATERTOWN, Mass., July 06, 2021 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ:KYMR), a clinical-stage biopharmaceutical company advancing targeted protein degradation to deliver novel small molecule protein degrader medicines, today announced the closing of its upsized underwritten public offering of 5,468,250 shares of its common stock at a public offering price of $47.00 per share, which includes 713,250 shares issued upon the exercise in full by the underwriters of their option to purchase additional shares of common stock. The gross proceeds from the offering, before deducting underwriting discounts and commissions and other offering expenses, were approximately $257.0 million.
- Kymera Therapeutics Announces Pricing of Upsized Public Offering of Common StockWATERTOWN, Mass., June 30, 2021 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ:KYMR), a clinical-stage biopharmaceutical company advancing targeted protein degradation to deliver novel small molecule protein degrader medicines, today announced the pricing of its upsized underwritten public offering of 4,755,000 shares of its common stock at a public offering price of $47.00 per share. All shares are being offered by Kymera. The gross proceeds from the offering, before deducting underwriting discounts and commissions and estimated offering expenses, are expected to be $223.5 million. In addition, Kymera has granted the underwriters a 30-day option to purchase up to an additional 713,
- Kymera Therapeutics Announces Proposed Public Offering of Common StockWATERTOWN, Mass., June 28, 2021 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ:KYMR), a clinical-stage biopharmaceutical company advancing targeted protein degradation to deliver novel small molecule protein degrader medicines, today announced that it has commenced an underwritten public offering of 4,000,000 shares of its common stock. All of the shares are being offered by Kymera. In addition, Kymera intends to grant the underwriters a 30-day option to purchase up to an additional 600,000 shares of its common stock. Morgan Stanley, J.P. Morgan, Cowen, and Guggenheim Securities are acting as joint book-running managers for the proposed offering. The offering is subject to market c